Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953703 · ClinicalTrials.gov registry record · Phase 2
Levocarnitine for Dry Eye in Sjogren's Syndrome
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03953703 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT03953703, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study evaluates the effectiveness of levocarnitine in the treatment of dry eye in adults with Sjogren's syndrome. This will be a crossover study design with all participants receiving both levocarnitine and placebo.
Interventions
- DRUG Placebo
- DRUG Levocarnitine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953703
The ClinicalTrials.gov registry entry for NCT03953703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03953703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953703 about?
NCT03953703 is a clinical study titled "Levocarnitine for Dry Eye in Sjogren's Syndrome". This study evaluates the effectiveness of levocarnitine in the treatment of dry eye in adults with Sjogren's syndrome. This will be a crossover study design with all participants receiving both levocarnitine and placebo.
What is the current status of trial NCT03953703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-11-17. Estimated completion is 2025-09-19.
What interventions are being tested in trial NCT03953703?
The interventions under investigation include: Placebo (DRUG), Levocarnitine (DRUG).
Who is sponsoring clinical trial NCT03953703?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.